Sustained high-efficiency daily diafiltration using a mediator-adsorbing membrane (SHEDD-fA) in the treatment of patients with severe sepsis

Contributions to Nephrology

Volumn 173, Issue , 2011, Pages 172-181

  Nishida, Osamu ^a   Nakamura, Tomoyuki ^a   Kuriyama, Naohide ^a   Hara, Yoshitaka ^a   Yumoto, Miho ^a   Shimomura, Yasuyo ^a   Moriyama, Kazuhiro ^a  

^a FUJITA HEALTH UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT; AUTACOID; CATECHOLAMINE; HLA DR ANTIGEN; IL6 PROTEIN, HUMAN; INTERLEUKIN 6; OXYGEN; POLY(METHYL METHACRYLATE);

ACUTE KIDNEY FAILURE; ADSORPTION; ADULT RESPIRATORY DISTRESS SYNDROME; AGED; ARTICLE; ARTIFICIAL MEMBRANE; BLOOD; CLASSIFICATION; EVALUATION; FEMALE; FLUID THERAPY; HEMODIAFILTRATION; HUMAN; INSTRUMENTATION; INTENSIVE CARE; MALE; METHODOLOGY; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; MULTIPLE ORGAN FAILURE; RETROSPECTIVE STUDY; SEPTIC SHOCK; SURVIVAL RATE; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; TREATMENT OUTCOME;

ACUTE KIDNEY INJURY; ADSORPTION; AGED; ANTI-BACTERIAL AGENTS; CATECHOLAMINES; COMBINED MODALITY THERAPY; CRITICAL CARE; FEMALE; FLUID THERAPY; HEMODIAFILTRATION; HLA-DR ANTIGENS; HUMANS; INFLAMMATION MEDIATORS; INTERLEUKIN-6; MALE; MEMBRANES, ARTIFICIAL; MIDDLE AGED; MULTIPLE ORGAN FAILURE; OXYGEN; POLYMETHYL METHACRYLATE; RESPIRATORY DISTRESS SYNDROME, ADULT; RETROSPECTIVE STUDIES; SHOCK, SEPTIC; SURVIVAL RATE; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; TREATMENT OUTCOME;

EID: 84958629257     PISSN: 03025144     EISSN: None     Source Type: Book Series    
DOI: 10.1159/000329057     Document Type: Article

References (23)

1. Rittirsch D, Flierl MA, Ward PA: Harmful molecular mechanisms in sepsis. Nat Rev Immunol 2008;8:776-787.
2. Ronco C, Tetta C, Mariano F, et al: Interpreting the mechanisms of continuous renal replacement therapy in sepsis: the peak concentration hypothesis. Artif Organs 2003;27:792-801.
3. Tracey KJ: Physiology and immunology of the cholingergic anti-inflammatory pathway. J Clin Invest 2007;117:289-296.
4. Piccinini AM, Midwood KS: DAMPening inflammation by modulating TLR signalling. Mediators Inflamm 2010;pii:672395.
5. Hirasawa H: Indications for blood purification in critical care. Contrib Nephrol. Basel, Karger, 2010, vol 166, pp 21-30.
6. Honoré PM, Jamez J, Wauthier M, et al: Prospective evaluation of short-term highvolume isovolemic hemofiltration on the hemodynamic course and outcome in patients with intractable circulatory failure resulting from septic shock. Crit Care Med 2000;28:3581-3587.
7. Morgera S, Haase M, Kuss T, et al: Pilot study on the effects of high cut-off hemofiltration on the need for norepinephrine in septic patients with acute renal failure. Crit Care Med 2006;34:2099-2104.
8. Ronco C, Kellum JA, Bellomo R, et al: Potential interventions in sepsis-related acute kidney injury. Clin J Am Soc Nephrol 2008;3:531-544.
9. Moriyama K, Soejima Y: Continuous hemodiafiltration using PMMA membrane: clinical efficacy and its mechanisms. Contrib Nephrol. Basel, Karger, 1999, vol 125, pp 222-232.
10. Nakada TA, Oda S, Matsuda K, et al: Continuous hemodiafiltration with PMMA hemofilter in the treatment of patients with septic shock. Mol Med 2008;14:257-263.
11. Chanard J, Lavaud S, Paris B, et al: Assessment of heparin binding to the AN69ST hemodialysis membrane. I. Preclinical studies. ASAIO J 2005;51:342-347.
12. Gong D, Zhang P, Ji D, et al: Improvement of immune dysfunction in patients with severe acute pancreatitis by high-volume hemofiltration: a preliminary report. Int J Artif Organs 2010;33:22-29.
13. Rimmele T, Assadi A, Cattenoz M, et al: High-volume haemofiltration with a new haemofiltration membrane having enhanced adsorption properties in septic pigs. Nephrol Dial Transplant 2009;24:421-427.
14. Nishida O, Nakamura T, Kuriyama N, et al: Sustained high-efficiency daily diafiltration using a cytokine-adsorbing membrane in the treatment of patients with severe sepsis. Crit Care 2011;15(suppl 1):115.
15. De Vriese AS, Colardyn FA, Philippé JJ, et al: Cytokine removal during continuous hemofiltration in septic patients. J Am Soc Nephrol 1999;10:846-853.
16. Yumoto M, Nishida O, Moriyama K, et al: In vitro evaluation of HMGB1 removal with various membranes for continuous hemofiltration. Crit Care 2011;5(suppl 1):114.
17. Cruz DN, Antonelli M, Fumagalli R et al: Early use of polymyxin B hemoperfusion in abdominal septic shock. JAMA 2009;301:2445-2452.
18. Fliser D, Kielstein JT: Technology Insight: treatment of renal failure in the intensive care unit with extended dialysis. Nat Clin Pract Nephrol 2006;2:32-39.
19. Yumoto M, Nishida O, Moriyama K, et al: In vitro evaluation of high mobility group box 1 protein removal with various membranes for continuous hemofiltration. Ther Apher Dial 2011 (in press).
20. Wang H, Ward MF, Sama AE: Novel HMGB1-inhibiting therapeutic agents for experimental sepsis. Shock 2009;32:348-357.
21. Bouman CSC: Antimicrobial dosing strategies in critically ill patients with acute kidney injury and high-dose continuous venovenous hemofiltration. Curr Opin Crit Care 2008;14:654-659.
22. Schiffl H: The dark side of high-intensity renal replacement therapy of acute kidney injury in critically ill patients. Int Urol Nephrol 2010;42:435-440.
23. Joannes-Boyau O, Honoré PM, Boer W, et al: Are the synergistic effects of high-volume haemofiltration and enhanced adsorption the missing key in sepsis modulation? Nephrol Dial Transplant 2009;24:354-357.